NCT05964413

Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum

A Randomized, Double-blind, Placebo-controlled, Multicenter, Adaptive Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in the Treatment of Ulcerative Pyoderma Gangrenosum

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 54 (actual)
• Sponsor: InflaRx GmbH · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum

Conditions

• Pyoderma Gangrenosum

Interventions

Type	Name	Description
DRUG	vilobelimab	vilobelimab infusion
DRUG	Placebo	Placebo Infusion

Timeline

• Start date: 2023-11-01
• Primary completion: 2025-07-11
• Completion: 2025-07-11
• First posted: 2023-07-27
• Last updated: 2025-11-04

Locations

50 sites across 10 countries: United States, Australia, Belgium, France, Germany, Hungary, Italy, Poland, Spain, Switzerland

Regulatory

• FDA-regulated drug study